Resources
Home
/
Resources
-
Adapting CMC Bioassay Strategies in Response to an Evolving ADC Pipeline
Speaker Presentation Hussman Patrick AstraZeneca 2024 -
Bioassays 2024 Scientific Program
Scientific Program: Bioassays 2024
-
Bioassays 2024 Summary Infographic
Summary Infographic: Bioassays 2024
-
When Simulation is Not Enough - When and Why Are Real World Studies of Shipping Needed
Roundtable 8 Notes: WCBP 2024
-
Visible and Sub-visible Particles - New Approaches and Requirements
Roundtable 18 Notes: WCBP 2024
-
Unlocking the Genetic Code - NGS Marvels in the Realm of Cell Therapy
Roundtable 21 Notes: WCBP 2024
-
Technical Transfer of Analytical Procedures - Approaches for Streamlining and Discussion of Regulatory Submissions Experiences
Roundtable 10 Notes: WCBP 2024
-
Supply Issues of New Medicines – Focus on Equitable Access in Third World Countries
Roundtable 12 Notes: WCBP 2024
-
Setting Specifications on Limited Data, Clinically Relevant Specs - Next Generation Control Strategies - Looking Ahead to Revision of ICH Q6B
Roundtable 1 Notes: WCBP 2024
-
Setting Specifications on Limited Data Clinically Relevant Specs - Next Generation Control Strategies - Looking Ahead to Revision of ICH Q6B - What is Needed
Roundtable 1 Notes: WCBP 2024
-
Role of Cryo-TEM as an Orthogonal Method to Help Assess Formulation Purity, Potency for Nanoparticles
Roundtable 16 Notes: WCBP 2024
-
Regulatory Expectations and Challenges: Lessons Learned from Developing Countries
Roundtable 12 Notes: WCBP 2024
-
Regulatory Considerations and Experiences for Control Strategies in Different Regions - Focus on General Challenges with Divergence
Roundtable 6 Notes: WCBP 2024
-
Regulatory Considerations and Experiences for Control Strategies in Different Regions
Roundtable 6 Notes: WCBP 2024
-
Regulator Review Preferences and Recent Review Trends: Questions and Key Issues - Focus on US FDA
Roundtable 4 Notes: WCBP 2024
-
Regulator Review Preferences and Recent Review Trends - Questions and Key Issues - Focus on Ex-US Regions
Roundtable 4 Notes: WCBP 2024
-
Recent Experiences with Regulation of Biosimilars at the FDA
Roundtable 15 Notes: WCBP 2024
-
Raw Material and Critical Reagent Control Strategies - Post Approval Challenges Including Shortages
Roundtable 16 Notes: WCBP 2024
-
Potency Assays - Use of Structure Function Models - MOA - Replace Biological - Cell-based Assays - Replacing in-vivo with in-vitro Potency Assays
Roundtable 5 Notes: WCBP 2024
-
NMR in Extended Characterization of Biologics
Roundtable 17 Notes: WCBP 2024